Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)

NCT02431754 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02431754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02431754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
February 29, 2016
Enrollment
171 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia